Insight

Goutham Sunny/LinkedIn

Jul 5, 2025, 16:06

Goutham Sunny: VISION Trial and Beyond

Goutham Sunny, Assistant Professor at The Gujarat Cancer and Research Institute, shared a post on X:

“Tepotinib in METex14 Skipping NSCLC – VISION Trial and Beyond

Background:

MET exon 14 skipping (METex14) occurs in ~3–4% of NSCLC cases
Patients often have poor outcomes with standard therapies
Tepotinib, an oral MET TKI, offers a targeted option

VISION Trial – Key Highlights:

Robust, durable efficacy in METex14+ NSCLC
Particularly effective in first-line setting
Consistent benefit across subgroups: Elderly and young, Asian patients, With/without brain metastases
Real-world evidence (RWE) supports trial data
Long-term safety manageable with preserved HRQOL (Health-Related Quality of Life)
Approved globally: Japan (2020), USA (2021 accelerated, 2024 full),

Mechanism:

Selective MET inhibition blocks MET-driven signaling → halts tumor growth and spread

Clinical Use Insights:

Tepotinib compares favorably vs chemo/IO in indirect analyses
Best outcomes observed when used early in treatment sequence
Guidance provided for adverse event management (e.g., peripheral edema)

Pros:

Oral targeted therapy with durable response
Effective even in brain metastases
Real-world validation of efficacy
Safe long-term with preserved QoL
First-line use may offer optimal outcomes

Cons:

Not curative – requires ongoing therapy
Resistance can develop
Side effects like edema require active management
Limited head-to-head comparative trial data

Significance:

Tepotinib represents a major step forward for a previously underserved NSCLC subset
Supports biomarker-driven precision oncology
VISION + RWE help inform optimal treatment sequencing and real-world applicability”

Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer

Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara Jr., Emmanuel Adewusi, Xiuning Li

You can read the Full Article on Cancer Treatment Reviews

Goutham Sunny: VISION Trial and Beyond

More posts featuring Goutham Sunny

cancer Emmanuel Adewusi Goutham Sunny Hatim Husain Lung cancer non small cell lung cancer NSCLC OncoDaily Oncology Paul K. Paik Richard M. O’Hara Jr. VISION trial Wade T. Iams Xiuning Li

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma

Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025

Lisa A. Lacasse Welcomed Shane Jacobson as the New CEO of the ACS and the ACS CAN

ASCO and Community Oncology Alliance Have Released the Updated Oncology Medical Home Standards